San Diego, California, USA, November 16, 2026
Protego Biopharma, Inc. has announced new clinical and preclinical findings supporting the development of PROT-001, an investigational oral small-molecule therapy for immunoglobulin light chain (AL) amyloidosis). The findings were presented across five scientific presentations at the XX International Symposium on Amyloidosis (ISA 2026), held from November 15–18, 2026. The data include results from a Phase 1 study in 102 healthy volunteers, laboratory investigations of cardiac-cell protection, compatibility with standard-of-care bortezomib-based treatment, and advances in the detection and monitoring of disease-associated light chains. PROT-001 is designed as a potential first-in-class lambda light chain kinetic stabilizer, intended to prevent abnormal light chain proteins from misfolding and forming toxic species that contribute to organ damage. The programme addresses an important unmet need in AL amyloidosis, where abnormal proteins can damage the heart and kidneys through both direct cellular toxicity and amyloid deposition. Protego believes that stabilizing these proteins could complement existing treatments that reduce their production. The new findings strengthen the scientific rationale for evaluating PROT-001 in the planned Phase 2/3 SHIELD-AL clinical study, following clearance of the company’s Investigational New Drug application by the U.S. Food and Drug Administration (FDA).
Phase 1 Study Shows Acceptable Safety and Tolerability
The first presentation reported findings from the PRO-1A-101 Phase 1 study, which evaluated PROT-001 in 102 healthy adult volunteers. The four-part study investigated safety, tolerability, pharmacokinetics, pharmacodynamics, food effects, and potential drug-drug interactions. Its design included single ascending doses, multiple ascending doses, an open-label food-effect assessment, and an open-label drug-interaction study. According to Protego, twice-daily oral administration was generally safe and well tolerated. The treatment achieved plasma concentrations associated with sustained ex-vivo stabilization of amyloidogenic lambda light chains, supporting its proposed mechanism of action. Pharmacokinetic and pharmacodynamic findings supported further development at 300–600 mg twice daily. These results provide early information about exposure and target-related activity, although the study was conducted in healthy volunteers rather than patients with AL amyloidosis. Consequently, it does not establish clinical efficacy or demonstrate improvements in organ function. The findings provide an initial clinical foundation for determining an appropriate dosing strategy in subsequent patient studies.
PROT-001 Demonstrates Potential Cardiac Protection
Cardiac involvement is a major concern in AL amyloidosis because abnormal light chains can directly affect heart muscle cells and contribute to progressive organ dysfunction. In laboratory investigations using human cardiomyocytes, amyloidogenic light chains reduced cell viability by more than 50%, whereas non-amyloidogenic light chains did not produce the same effect. PROT-001 restored cardiomyocyte viability in a dose-dependent manner and selectively suppressed the expression of B-type natriuretic peptide (BNP) and troponin, markers associated with cardiac stress and cellular injury. These findings suggest that stabilizing abnormal light chains may help reduce their harmful effects on heart cells. A separate investigation assessed PROT-001 alongside bortezomib, a component of commonly used plasma cell-directed treatment regimens. The laboratory data indicated that PROT-001 did not reduce bortezomib’s plasma cell-killing activity or worsen its toxic effects on human heart cells. This compatibility could support further investigation of the compound as a complementary treatment. However, these findings are based on laboratory models and do not yet demonstrate cardiac protection or improved outcomes in patients.
AmyLiteDx and Cardiac Biomarker Research Support Development
Protego also presented findings involving AmyLiteDx, a mass spectrometry-based platform designed to provide more detailed characterization of amyloidogenic immunoglobulin light chains. Conventional immunoassays measure circulating light chain concentrations but do not directly assess protein instability. AmyLiteDx is intended to provide additional information about unstable and potentially toxic light chains alongside established biomarkers. Another retrospective study examined NT-proBNP, a marker of cardiac stress, in newly diagnosed patients with Mayo stage II–IIIb AL amyloidosis receiving standard-of-care treatment. Among patients who achieved a cardiac organ response at six months, reductions in NT-proBNP were most apparent within the first 28 days. Early cardiac response was also associated with improved long-term overall survival. These observations highlight the potential importance of early biomarker changes in monitoring disease response, although retrospective associations do not establish causation. Collectively, the five presentations provide clinical, laboratory, and biomarker evidence supporting further investigation of PROT-001. The planned SHIELD-AL Phase 2/3 study will evaluate the investigational treatment in patients with AL amyloidosis alongside standard care. PROT-001 remains investigational and has not been approved as a treatment. Future clinical studies must establish its safety and whether the promising early findings translate into meaningful patient benefits.
Source: Protego Biopharma press release



